{
  "id": 3739334,
  "title": "Celularity to manufacture Dezawa MuseCells for MuseCell Innovations",
  "url": "https://urgent.news/2026/08/27/celularity-to-manufacture-dezawa-musecells-for-musecell-innovations",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-27T13:04:37.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/celularity-to-manufacture-dezawa-musecells-for-musecell-innovations-93CH-4879474"
  },
  "original_language": "en",
  "account": "Florham Park, New Jersey and Singapore - Celularity Inc., a company traded on the NASDAQ under the ticker symbol CELU, has announced a manufacturing partnership with MuseCell Innovations Pte. Ltd. The agreement will establish a U.S. production site for Dezawa MuseCells at Celularity's facility in Florham Park, New Jersey. The initial program will focus on manufacturing Dezawa MuseCells using a licensed method known as the Dezawa Method. This collaboration also extends to the production of products derived from Dezawa MuseCells, such as Dezawa MuseExosomes and Dezawa MuseSecretome. According to MuseCell Innovations, if the partnership expands, it could result in over $300 million in combined purchases from Celularity within the next five years, based on current market trends and projections for the Dezawa MuseCell platform. The initial program is expected to generate more than 200 job opportunities at the Florham Park site, covering roles in biomanufacturing, quality control, engineering, and support functions.\n\nRobert J. Hariri, the Founder, Chairman, and Chief Executive Officer of Celularity, emphasized that cellular medicine is a central aspect of the company's strategy. He added that the collaboration with MuseCell Innovations showcases how the manufacturing infrastructure and cellular expertise Celularity has developed can be utilized to support innovative third-party technologies. The Dezawa MuseCells are a naturally occurring cell population discovered by Professor Mari Dezawa, with their biology and investigational applications documented in more than 170 peer-reviewed publications and evaluated in multiple human clinical studies. As of now, neither cenplacel-L nor any MuseCell Innovations product has received approval from the U.S. Food and Drug Administration.",
  "summary": null,
  "key_points": [
    "Celularity and MuseCell Innovations partner to manufacture Dezawa MuseCells in Florham Park, NJ.",
    "Collaboration expected to create over 200 jobs and generate $300M+ in purchases over five years."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}